{"cord_uid": "m6abyuvx", "sourcedb": "PMC", "sourceid": "PMC3524174", "divid": "33", "text": "In conclusion , our findings demonstrated that rVV - N25 is a promising candidate for an HCV vaccine therapy . Additionally , the findings of this study indicate that rVV - N25 immunization can be used for prevention of HCV infection and as an antiviral therapy against ongoing HCV infection .", "project": "cdlai_CORD-19", "denotations": [{"id": "A-biobert_T1", "span": {"begin": 89, "end": 93}, "obj": "Disease"}, {"id": "A-biobert_T2", "span": {"begin": 220, "end": 234}, "obj": "Disease"}, {"id": "A-biobert_T3", "span": {"begin": 278, "end": 292}, "obj": "Disease"}]}